ArticleTranslational cancer research2020
Novel poly-β-cyclodextrin derivatives as advanced carriers for 5-fluorouracil for tumor: the impact of charge on antitumor efficiency.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Chitosan/β-cyclodextrin nanocarriers enhance 5-fluorouracil efficacy against colorectal cancer via pH-responsive release and apoptosis modulation.Scientific reports · 2026Article
- Cyclodextrin-Based Nanocarriers for 5-Fluorouracil: Cholesteryl Modification Enhances Antitumor Activity Against Colorectal Cancer Cells.International journal of nanomedicine · 2026Article
- 5-FU@DHA-UIO-66-NHAnnals of translational medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the emergence of more and more cyclodextrin derivatives, cyclodextrin becomes an effective adjuvant for improving the prescription of drugs. Its application in pharmacy, especially in the sustained and controlled release, targeting, transdermal and mucosal drug delivery systems, is also being expanded and deepened. In this study, novel cyclodextrin derivatives were developed to investigate the impact of the charge on antitumor efficiency by introducing different groups (carboxymethyl or quaternary ammonium group) to poly-β-cyclodextrin (β-CD).
methodsThese novel β-CD derivatives were prepared by the nucleophilic substitution reaction and characterized by IR and
resultsThe results of IR and 1H NMR indicated consistently that both carboxymethyl poly-β-CD (poly-CM-β-CD) and glycidyl trimethyl ammonium chloride (GTMAC) poly-β-CD (poly-GTAC-β-CD) were successfully prepared. Fluorouracil was successfully loaded into poly-β-CD derivatives. The results of fluorine analysis indicated that the content of 5-FU in 1 g poly-β-CD, poly-GTAC-β-CD and poly-CM-β-CD was 1,214, 921 and 1,187 µg, respectively. No cytotoxicity of poly-β-CD derivatives on HepG2 cells was observed. The killing effect of poly-β-CD-5-FU on HepG2 cells was similar to that of poly-GTAC-β-CD-5-FU. Poly-CM-β-CD-5-FU had the worst killing effect on HepG2 cells.
conclusionsCharge had impact on antitumor efficiency. These novel poly-β-CD derivatives have potential applications in tumor sustained-release targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.